TY - JOUR
T1 - Impact of concomitant treatment of non-chronic total occlusion lesions at the time of chronic total occlusion intervention
AU - Xenogiannis, Iosif
AU - Karmpaliotis, Dimitri
AU - Alaswad, Khaldoon
AU - Jaffer, Farouc A.
AU - Yeh, Robert W.
AU - Patel, Mitul
AU - Mahmud, Ehtisham
AU - Choi, James W.
AU - Burke, M. Nicholas
AU - Doing, Anthony H.
AU - Dattilo, Phil
AU - Toma, Catalin
AU - Uretsky, Barry
AU - Krestyaninov, Oleg
AU - Khelimskii, Dmitrii
AU - Holper, Elizabeth
AU - Potluri, Srinivasa
AU - Wyman, R. Michael
AU - Kandzari, David E.
AU - Garcia, Santiago
AU - Koutouzis, Michalis
AU - Tsiafoutis, Ioannis
AU - Khatri, Jaikirshan J.
AU - Jaber, Wissam
AU - Samady, Habib
AU - Jefferson, Brian K.
AU - Patel, Taral
AU - Moses, Jeffrey W.
AU - Lembo, Nicholas J.
AU - Parikh, Manish
AU - Kirtane, Ajay J.
AU - Ali, Ziad A.
AU - Gkargkoulas, Fotis
AU - Tajti, Peter
AU - Hall, Allison B.
AU - Rangan, Bavana Venkata
AU - Abdullah, Shuaib
AU - Banerjee, Subhash
AU - Brilakis, Emmanouil S.
N1 - Funding Information:
Dr. Kandzari: research grant: Boston Scientific and Medtronic Cardiovascular, Abbott. Consultant/Advisory Board: Boston Scientific and Medtronic Cardiovascular.
Funding Information:
Dr. Rangan: research grants from InfraReDx, Inc., and The Spectranetics Corporation.
Funding Information:
Dr. Khatri: research grant support: Asahi Intecc. Speaker/Proctor: Abbott Vascular.
Funding Information:
Dr. Ali: consultant fees/honoraria from St. Jude Medical, and AstraZeneca Pharmaceuticals; ownership interest/partnership/principal in Shockwave Medical and VitaBx Inc.; and research grants from Medtronic and St. Jude Medical.
Funding Information:
Dr. Banerjee: research grants from Gilead and the Medicines Company; consultant/speaker honoraria from Covidien and Medtronic; ownership in MDCARE Global (spouse); intellectual property in HygeiaTel.
Funding Information:
Study data were collected and managed using Research Electronic Data Capture (REDCap) electronic data capture tools hosted at the Minneapolis Heart Institute Foundation (MHIF), Minneapolis, Minnesota. REDCap is a secure, web-based application designed to support data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources. The Progress CTO registry has received support from the Abbott Northwestern Hospital Foundation, Minneapolis, MN. Dr. Xenogiannis: nothing to disclose. Dr. Karmpaliotis: speaker honoraria: Abbott Vascular and Boston Scientific. Dr. Alaswaad: consulting fees from Terumo and Boston Scientific; consultant, no financial, Abbott Laboratories. Dr. Jaffer: consultant: Abbott Vascular, Boston Scientific and Siemens. Research grant: Canon, Siemens and National Institutes of Health. Dr. Yeh: career development award (1K23HL118138) from the National Heart, Lung, and Blood Institute. Dr. M. Patel: speakers' bureau for Astra Zeneca. Dr. Mahmud: consulting fees from Medtronic and Corindus; speaker's fees from Medtronic, Corindus, and Abbott Vascular; educational program fees from Abbott Vascular; and clinical events committee fees from St. Jude. Dr. Choi: nothing to disclose. Dr. Burke: consulting and speaker honoraria from Abbott Vascular and Boston Scientific. Dr. Doing: nothing to disclose. Dr. Datillo: nothing to disclose. Dr. Toma: nothing to disclose. Dr. Uretsky: nothing to disclose. Dr. Krestyaninov: nothing to disclose. Dr. Khelimskii: nothing to disclose. Dr. Holper: nothing to disclose. Dr. Potluri: nothing to disclose. Dr. Wyman: speakers bureau: Boston Scientific, Abbott Vascular, and Asahi. Honoraria: Boston Scientific, Abbott Vascular, and Asahi. Consultant/Advisory Board: Boston Scientific, Abbott Vascular, and Asahi. Dr. Kandzari: research grant: Boston Scientific and Medtronic Cardiovascular, Abbott. Consultant/Advisory Board: Boston Scientific and Medtronic Cardiovascular. Dr. Garcia: consulting fees from Medtronic. Dr. Koutouzis: nothing to disclose. Dr. Tsiafoutis: nothing to disclose. Dr. Khatri: research grant support: Asahi Intecc. Speaker/Proctor: Abbott Vascular. Dr. Jaber: nothing to disclose. Dr. Samady: nothing to disclose. Dr. Jefferson: honoraria/consulting/speaking fees from Abbott, Boston Scientific, CSI, Medtronic. Dr. T. Patel: nothing to disclose. Dr. Moses: consultant to Boston Scientific and Abiomed. Dr. Lembo: speaker bureau: Medtronic. Consultant/Advisory Board: Abbott Vascular and Medtronic. Dr. Parikh: speaker bureau: Abbot Vascular, Medtronic, CSI, BSC, Trireme; advisory boards: Medtronic, Abbott Vascular, Philips. Dr. Kirtane: Institutional research grants to Columbia University from Boston Scientific, Medtronic, Abbott Vascular, Abiomed, St. Jude Medical, Vascular Dynamics, Glaxo SmithKline, and Eli Lilly. Dr. Ali: consultant fees/honoraria from St. Jude Medical, and AstraZeneca Pharmaceuticals; ownership interest/partnership/principal in Shockwave Medical and VitaBx Inc.; and research grants from Medtronic and St. Jude Medical. Dr. Gkargkoulas: nothing to disclose. Dr. Tajti: nothing to disclose. Dr. Hall: nothing to disclose. Dr. Rangan: research grants from InfraReDx, Inc. and The Spectranetics Corporation. Dr. Abdullah: nothing to disclose. Dr. Banerjee: research grants from Gilead and the Medicines Company; consultant/speaker honoraria from Covidien and Medtronic; ownership in MDCARE Global (spouse); intellectual property in HygeiaTel. Dr. Brilakis: consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Amgen, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), CSI, Elsevier, GE Healthcare, and Medtronic; research support from Siemens, Regeneron, and Osprey. Shareholder: MHI Ventures. Board of Trustees: Society of Cardiovascular Angiography and Interventions.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2020/1/15
Y1 - 2020/1/15
N2 - Background: During chronic total occlusion (CTO) percutaneous coronary intervention (PCI), sometimes non-CTO lesions are also treated. Methods: We compared the clinical and procedural characteristics and outcomes of CTO PCIs with and without concomitant treatment of a non-CTO lesion in a contemporary multicenter CTO registry. Results: Of the 3598 CTO PCIs performed at 21 centers between 2012 and 2018, 814 (23%) also included PCI of at least one non-CTO lesion. Patients in whom non-CTO lesions were treated were older (65 ± 10 vs. 64 ± 10 years, p = 0.03), more likely to present with an acute coronary syndrome (32% vs. 23%, p < 0.01), and less likely to undergo PCI of a right coronary artery (RCA) CTO (46% vs. 58%, p < 0.01). The most common non-CTO lesion location was the left anterior descending artery (31%), followed by the circumflex (29%) and the RCA (25%).Combined non-CTO and CTO-PCI procedures had similar technical (88% vs. 87%, p = 0.33) and procedural (85% vs. 85%, p = 0.74) success and major in-hospital complication rates (3.4% vs. 2.7%, p = 0.23), but had longer procedure duration (131 [88, 201] vs. 117 [75, 179] minutes, p < 0.01), higher patient air kerma radiation dose (3.0 [1.9, 4.8] vs. 2.8 [1.5, 4.6] Gray, p < 0.01) and larger contrast volume (300 [220, 380] vs. 250 [180, 350] ml, p < 0.01). Conclusions: Combined CTO PCI with PCI of non-CTO lesions is associated with similar success and major in-hospital complication rates compared with cases in which only CTOs were treated, but requires longer procedure duration and higher radiation dose and contrast volume.
AB - Background: During chronic total occlusion (CTO) percutaneous coronary intervention (PCI), sometimes non-CTO lesions are also treated. Methods: We compared the clinical and procedural characteristics and outcomes of CTO PCIs with and without concomitant treatment of a non-CTO lesion in a contemporary multicenter CTO registry. Results: Of the 3598 CTO PCIs performed at 21 centers between 2012 and 2018, 814 (23%) also included PCI of at least one non-CTO lesion. Patients in whom non-CTO lesions were treated were older (65 ± 10 vs. 64 ± 10 years, p = 0.03), more likely to present with an acute coronary syndrome (32% vs. 23%, p < 0.01), and less likely to undergo PCI of a right coronary artery (RCA) CTO (46% vs. 58%, p < 0.01). The most common non-CTO lesion location was the left anterior descending artery (31%), followed by the circumflex (29%) and the RCA (25%).Combined non-CTO and CTO-PCI procedures had similar technical (88% vs. 87%, p = 0.33) and procedural (85% vs. 85%, p = 0.74) success and major in-hospital complication rates (3.4% vs. 2.7%, p = 0.23), but had longer procedure duration (131 [88, 201] vs. 117 [75, 179] minutes, p < 0.01), higher patient air kerma radiation dose (3.0 [1.9, 4.8] vs. 2.8 [1.5, 4.6] Gray, p < 0.01) and larger contrast volume (300 [220, 380] vs. 250 [180, 350] ml, p < 0.01). Conclusions: Combined CTO PCI with PCI of non-CTO lesions is associated with similar success and major in-hospital complication rates compared with cases in which only CTOs were treated, but requires longer procedure duration and higher radiation dose and contrast volume.
KW - Chronic total occlusions
KW - Percutaneous coronary interventions
UR - http://www.scopus.com/inward/record.url?scp=85068523847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068523847&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2019.06.077
DO - 10.1016/j.ijcard.2019.06.077
M3 - Article
C2 - 31301862
AN - SCOPUS:85068523847
SN - 0167-5273
VL - 299
SP - 75
EP - 80
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -